Loading…
Profusa, Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
None of the investors we track reported a position in PFSA.
▼ -100.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| BJDXBluejay Diagnostics, Inc. | $0.90 | — | 0.2x | — | -98.89% | $931.24K |
| BDRXBiodexa Pharmaceuticals Plc | $0.87 | — | 0.0x | — | -64.72% | $893.33K |
| NIVFNewGenIvf Group Ltd | $0.34 | 0.0x | 0.0x | — | 79.40% | $833.53K |
| CDTCDT Equity Inc. | $1.69 |
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Company description provided by Yahoo Finance.
| — |
| 0.0x |
| — |
| -69.68% |
| $1.33M |
| VTAKCatheter Precision, Inc. | $0.20 | — | 0.0x | — | -111.35% | $724.42K |
| SXTCChina SXT Pharmaceuticals, Inc. | $3.00 | — | 0.1x | — | -27.49% | $1.6M |